Evaluation of the Diagnostic Utility of INS316 in Patients With Interstitial Lung Diseases (01-701)
NCT ID: NCT01381666
Last Updated: 2015-10-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
22 participants
INTERVENTIONAL
2003-01-31
2004-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
High Dose Inhaled Mannitol Study
NCT01076491
A Pilot Study to Investigate Administration of Mannitol Via a Novel Dry Powder Inhaler Device
NCT00730977
The Study of the Use of Nintedanib in Slowing Lung Disease in Patients With Fibrotic or Non-Fibrotic Interstitial Lung Disease Related to COVID-19
NCT04619680
Safety and Efficacy of Bronchitol in Bronchiectasis
NCT00277537
Sputum Cytometry Guided Management for the Elimination of Chronic Cough in Patients With ILD
NCT05086432
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
INS316
inhalation via nebulizer given for 2 doses for 60 minutes each
INS316 solution for inhalation
inhalation via nebulizer given for 2 doses for 60 minutes each
hypertonic saline 3% sodium chloride solution
inhalation via nebulizer given for 2 doses for 60 minutes each
hypertonic saline 3% sodium chloride solution
inhalation via nebulizer given for 2 doses for 60 minutes each
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
INS316 solution for inhalation
inhalation via nebulizer given for 2 doses for 60 minutes each
hypertonic saline 3% sodium chloride solution
inhalation via nebulizer given for 2 doses for 60 minutes each
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* undergone diagnostic bronchoalveolar lavage within the previous 21 days
* diagnosed with sarcoidosis or other ILD
Exclusion Criteria
* receiving corticosteroid treatment
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
01-701
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.